Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Bristol-Myers Squibb enters the final stretch before its October 29 earnings with a notable shift in the short-selling picture and a fresh analyst downgrade from a prominent house, two signals pointing in opposite directions that make the setup more complicated than last week's note suggested.
The most consequential change from the September 30 note is the reversal in short interest. What was a steadily declining bear position has snapped back sharply. Short interest jumped roughly 20% over the past week to 2.5% of the free float, a meaningful acceleration even if the absolute level remains modest. The move came in a stock that fell 5.2% on the week to $59.59, suggesting some of the new shorts are following, or anticipating, further price weakness. Cost to borrow has climbed 140% week-on-week to just under 0.50%, the highest in the 30-day window, though in absolute terms it remains cheap. The borrow market is far from stressed: availability is effectively unlimited, with shares available to lend at more than 75 times the current short interest. This is a directional bet, not a squeeze setup.
Options positioning has stayed defensive but not escalated materially. The put/call ratio dipped slightly to 1.04 from last week's 1.05, remaining above its 20-day average of 1.03 and well above the 0.90 level that prevailed in early September. The z-score of 0.17 is now barely above neutral, so the hedging tilt documented last week has not intensified further, even as short sellers added positions. Taken together, the positioning picture shows bears building modestly via the stock loan market while options traders hold their protective puts but aren't adding aggressively.
The analyst picture sharpened this week. Leerink Partners cut its rating on BMY to Market Perform from Outperform on October 5, slashing its target from $73 to $59, effectively eliminating the upside premium it had previously assigned the stock. That move landed the day after Morgan Stanley's Terence Flynn raised his target by a dollar to $41 while keeping an Underweight rating, the most bearish published target among the visible recent changes. Those two moves bracket a wide range of Street opinion: Piper Sandler has an Overweight with an $82 target, JP Morgan sits at Overweight with $73, while Cantor Fitzgerald and Wells Fargo both cluster around $59 to $65 with neutral-equivalent ratings. The mean price target of $66 implies roughly 11% upside from the current price, but the Leerink cut suggests at least one previously bullish analyst now sees the stock fairly valued at these levels. The bull case centres on Opdivo, Eliquis, and the 10 to 15% Eliquis growth target for the year; the bear case flags competition, pipeline risk, and heavy US revenue concentration.
One alternative data point worth noting: Medicaid dollars reimbursed for BMY drugs fell 26% year-on-year in Q1 2026, with Medicaid prescription volumes down 11% in the same period. None of the alt-data datasets covering BMY have been measured as leading indicators for its reported revenue, so no predictive inference is warranted. But the Medicaid figures, published by the Centers for Medicare and Medicaid Services, are a factual read on government-channel pressure that adds texture to the bear case around US revenue exposure.
The stock has now shed nearly 11% over the past month. Close peers have fared only marginally better: MRK fell 4.9% on the week and JNJ dropped 4.8%, suggesting broad sector pressure rather than a BMY-specific problem. BHC was the outlier, gaining 3.8% on the week. Earnings history for BMY shows the stock rose 3.5% the day after its July 2026 print, and fell 1.4% after the May 2026 result, two modest moves that give limited directional guidance for October 29.
What to watch next: whether short interest continues building toward and through the earnings date, and whether the Leerink downgrade prompts further consensus target compression on a stock where the most bearish Street voice is now calling $41.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
